EGFR and neoplasm: Furthermore, the clinical relevance of this is increased by findings which suggest that, consistent with observation in other tumour types, EGFR signalling is a key determinant of resistance to immune checkpoint inhibitors in ESCC [29], and accordingly EGFR-driven ESCC are likely to be a subgroup that derive less, or no, benefit from immune checkpoint inhibitors.